Therapeutic effects and prognosis of entecavir and thymosin alpha 1 on hepatitis B cirrhosis patients with diabetes

Abstract

Objective To investigate the efficacy and prognosis of entecavir combined with thymosin α1 on hepatitis B cirrhosis patients with hepatogenous diabetes. Methods A total of 160 cases of hepatitis B cirrhosis with diabetes in the Fourth People’s Hospital of Datong from January 2016 to December 2017 were selected as the research subjects, and they were randomly divided into the control group and the experimental group, with 80 cases in each group. The control group was given entecavir treatment and clinical routine liver protection treatment. The experimental group was treated with thymosin α 1 on the basis of the treatment in the control group. The differences of symptoms and signs and biochemical indexes before and after treatment in the two groups were compared. The the incidences of adverse drug reactions were calculated, and the prognosis of the two groups was analyzed. Results After treatment, the symptoms and signs, liver function indexes, liver fibrosis indexes and glycometabolism indexes were improved in the two groups (P<0.05); there were significant differences in the symptoms and signs, liver function indexes, liver fibrosis indexes and glucose metabolism indexes between the two groups (P<0.05). In the experimental group, the improvement rates of asthenia, anorexia, abdominal distention were higher, liver function indexes recovered better, liver fibrosis degree decreased, and glucose metabolism levels recovered better. The incidence of adverse drug reaction in the experimental group was 5%, which was lower than that in the control group (15%, P<0.05). The negative rate of HBV-DNA and the negative rate of HBeAg in the experimental group were higher than those in the control group (P<0.05). Conclusions The effect of entecavir and thymosin α 1 on hepatitis B cirrhosis with diabetes is better than single drug, which has higher safety, and can reduce the incidence of ill prognosis. Key words: Entecavir; Thymosin α1; Cirrhosis; Diabetes mellitus; Hepatitis B; Clinical efficacy; Prognosis